|
About Sanofi-aventis
Sanofi-aventis is committed to addressing the tough challenges facing healthcare professionals and their patients. With cancer being a leading cause of death in the world today, innovative solutions in cancer care are critical. At sanofi-aventis, we share this sense of urgency. That's why we strive for new solutions that will improve the lives of cancer patients.
Our Products
We've been pioneers in the development of cytotoxic agents, including Taxotere® (docetaxel) Injection Concentrate, Eloxatin® (oxaliplatin injection), and supportive-care products, such as Lovenox® (enoxaparin sodium injection), Anzemet® (dolasetron mesylate injection), Anzemet® (dolasetron mesylate tablets) and Elitek™ (rasburicase). Today, these agents play a major role throughout the world in the treatment of certain types of cancer or the management of side effects.
 | Indications and Important Safety Information for Anzemet
ANZEMET® (dolasetron mesylate) Injection - Full Prescribing Information
ANZEMET® is indicated for the prevention and treatment of chemotherapy-induced nausea and/or vomiting.
ANZEMET® (dolasetron mesylate) Tablets - Full Prescribing Information
ANZEMET® is indicated for the prevention and treatment of chemotherapy-induced nausea and/or vomiting.
The most common adverse events (> 2%) in chemotherapy patients are headache, fatigue, diarrhea, and bradycardia (tablets); and headache, diarrhea, and fever (injection). Anzemet® can cause ECG interval changes; it should be administered with caution in patients who have or may develop prolongation of cardiac conduction intervals. |
|
 ANZEMET Injection is indicated for the following:
(1) the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high dose cisplatin;
(2) the prevention of postoperative nausea and vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ANZEMET Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low;
(3) the treatment of postoperative nausea and/or vomiting. ANZEMET Tablets are indicated for:
1) the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses;
2)the prevention of postoperative nausea and vomiting.  INDICATIONS AND USAGE
Breast Cancer
TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
Non-Small Cell Lung Cancer
TAXOTERE as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
TAXOTERE in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
Prostate Cancer
TAXOTERE in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. |
